Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study by Zammit, Stanley et al.
Papers
Self reported cannabis use as a risk factor for
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historical cohort study
Stanley Zammit, Peter Allebeck, Sven Andreasson, Ingvar Lundberg, Glyn Lewis
Abstract
Objectives An association between use of cannabis in
adolescence and subsequent risk of schizophrenia was
previously reported in a follow up of Swedish
conscripts. Arguments were raised that this
association may be due to use of drugs other than
cannabis and that personality traits may have
confounded results. We performed a further analysis
of this cohort to address these uncertainties while
extending the follow up period to identify additional
cases.
Design Historical cohort study.
Setting 1969›70 survey of Swedish conscripts ( > 97%
of the country’s male population aged 18›20).
Participants 50 087 subjects: data were available on
self reported use of cannabis and other drugs, and on
several social and psychological characteristics.
Main outcome measures Admissions to hospital for
ICD›8/9 schizophrenia and other psychoses, as
determined by record linkage.
Results Cannabis was associated with an increased
risk of developing schizophrenia in a dose dependent
fashion both for subjects who had ever used cannabis
(adjusted odds ratio for linear trend of increasing
frequency 1.2, 95% confidence interval 1.1 to 1.4,
P < 0.001), and for subjects who had used only
cannabis and no other drugs (adjusted odds ratio for
linear trend 1.3, 1.1 to 1.5, P < 0.015). The adjusted
odds ratio for using cannabis > 50 times was 6.7 (2.1
to 21.7) in the cannabis only group. Similar results
were obtained when analysis was restricted to subjects
developing schizophrenia after five years after
conscription, to exclude prodromal cases.
Conclusions Cannabis use is associated with an
increased risk of developing schizophrenia, consistent
with a causal relation. This association is not
explained by use of other psychoactive drugs or
personality traits relating to social integration.
Introduction
The relation between cannabis use and subsequent
onset of psychosis is complex.1–3 Although it is clear
that high doses of cannabis may lead to a short lived
toxic psychosis, it is unclear whether cannabis increases
the risk of psychotic illness persisting after abstinence
from the drug. An association between self reported
use of cannabis in adolescence and subsequent risk of
schizophrenia was reported from a cohort study of
Swedish conscripts,4 which supports the view that can›
nabis might act as an independent risk factor for
schizophrenia. Several uncertainties have, however,
been raised regarding the interpretation of this result.
Firstly, the apparent effect of cannabis may be
caused by other drugs (such as amphetamines) that are
more likely to have been misused among cannabis
users than among non›users.5 6 Secondly, premorbid
personality traits may have predisposed individuals
both to developing schizophrenia and to using canna›
bis. Traits relating to social behaviour are likely to be
particularly important in this respect. Thirdly, use of
cannabis may have been secondary to the presence of
schizophrenia, as a form of “self medication” for symp›
toms, despite failure to identify the disorder at the time
of conscription.7 Review of case histories of a small
subsample from this cohort shows that the association
was not due to use of other drugs and that use of can›
nabis preceded any mental illness,8 but the causal path›
ways are difficult to disentangle and merit further
study.
We are not aware of any other cohort studies that
have investigated the association between drug use and
subsequent risk of schizophrenia, and case›control
studies are susceptible to recall bias. In this study we
perform a further analysis of the Swedish conscript
cohort to address some of the above concerns.4 The
follow up period is now 27 years (15 years in the origi›
nal study) and covers almost the whole period of risk
for schizophrenia.9 Our improved understanding of
risk factors for schizophrenia has also enabled us
better to adjust for factors such as personality traits
that potentially confound this relation.10–13
Methods
Subjects
The cohort consisted of 50 087 Swedish men
conscripted for compulsory military training in
1969›1970. More than 98% (49 321) were 18›20 years
of age. Only 2›3% of the male population were excused
conscription because of severe mental or physical
handicap. The conscription procedure included intelli›
gence tests and non›anonymous self reported ques›
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tionnaires on family, social background, behaviour
during adolescence, and substance use—including first
drug used, drug most commonly used, frequency of
use, and direct questions regarding use of a list of
specified drugs. Details of the procedure and results of
studies of its validity have been reported previously.14
All subjects underwent a structured interview con›
ducted by a psychologist, and those reporting any psy›
chiatric symptoms were interviewed by a psychiatrist
and given a diagnosis according to ICD›8 (inter›
national classification of diseases, 8th revision) where
applicable.15 Thirty four cases of psychosis diagnosed
at conscription were excluded from the study.
Permission to use the anonymised database was
granted by the Karolinska Institute research ethics
committee and the Swedish data inspection board.
Follow up
The Swedish national hospital discharge register
recorded about 70% of all psychiatric admissions in
1970, rising to 83% in 1973. Coverage was 97% in
1974›83, 95% in 1984›6, and has been virtually
complete since 1987. The linkage reported here was
from 1970 to 1996. The incomplete registration during
some periods is unlikely to have affected the results.
Misclassification of outcomes is likely to be low, given
that over 90% of people with schizophrenia are admit›
ted to hospital at some point during their illness.16
Patients were given clinical diagnoses according to
the Nordic version of ICD›8 (ICD›9 from 1987).
Outcomes investigated were schizophrenia (codes
295.00›295.99) and other psychoses (including affec›
tive and paranoid psychoses, codes 296.00›298.99). It is
unlikely that cases diagnosed as schizophrenia in this
cohort were either toxic psychoses induced by
cannabis (or amphetamine) or acute, transient drug
induced psychoses, given the restrictive tradition in
Sweden regarding the diagnosis of schizophrenia.17
Satisfactory validity of schizophrenia diagnoses in a
small sample from this cohort has been observed,8 and
ICD›8 diagnoses from the register have shown high
specificity with criteria for schizophrenia as defined in
DSM›III (Diagnostic and Statistical Manual of Mental
Disorders, third edition).18
Analysis
We used logistic regression to calculate odds ratios and
95% confidence intervals for developing schizophrenia
in subjects who used cannabis compared with subjects
with no history of drug use, both before and after
adjustment for potential confounders. Odds ratios may
be interpreted as rate ratios because schizophrenia is a
rare outcome.19 Although a few subjects died during
follow up, analysis by using Cox regression made no
difference to the results obtained by using logistic
regression, which we therefore retained as the method
of choice.
Previous research has found that psychiatric
diagnosis at conscription, IQ score, personality
variables concerned with interpersonal relationships,
place of upbringing, paternal age, and cigarette smok›
ing are all associated with schizophrenia.10–13 20 21 We
included these variables as potential confounders in
the regression model. Disturbed behaviour in child›
hood, history of alcohol misuse, family history of
psychiatric illness, financial situation of the family, and
father’s occupation were also considered to be
potential confounders and included in the analysis.
The variable relating to poor social integration as an
aspect of personality was a summed score of questions
regarding number of close friends, history of relation›
ships with girlfriends, and individual sensitivity. We
selected these questions after a factor analysis of over
40 questions relating to childhood and adolescent
behaviour from one of the questionnaires. Only 3% of
the sample had missing data for any of the questions.
Subjects were stratified into those receiving a diag›
nosis within five years of conscription (0›5 years) and
those receiving a diagnosis after this time ( > 5 years) to
investigate possible effects of a prodrome at the time of
conscription.
Results
Out of the 50 053 subjects, 362 (0.71%, 95%
confidence interval 0.65% to 0.80%) received a diagno›
sis of schizophrenia by 1996. Data on drug use, derived
from all sources of information, were missing on 16
(4.4%) of subjects developing schizophrenia and on
1522 (3.1%) of non›cases (P < 0.2).
Of 11 variables initially included as potential
confounders, only five had any effect on the adjusted
results. Table 1 shows a summary of these in relation to
cannabis use. Adjusting for poor social integration
made minimal difference to results but is also included
in table 1. For the purposes of table 1 only, we treated
IQ score, poor social integration, and disturbed behav›
iour as dichotomous variables, using the 10th
percentile as a cut›off point for coding.
Ever used cannabis
Altogether 5391 subjects (10.8% of the cohort) had
ever used cannabis, and 73 of these (1.4%) developed
schizophrenia. In 69 subjects who started using drugs
before 1969, 19 (31%; 95% confidence interval 20% to
44%) of those developing schizophrenia had stopped
using drugs before conscription, as opposed to 2810
(64%; 62% to 65%) of the 4418 who did not develop
schizophrenia (P < 0.001).
Table 1 Summary of confounders in relation to subjects’ history of drug use at conscription. Values are numbers (percentages) of
cohort sample
Subjects by type of drug use
Diagnosis of
psychiatric illness on
conscription*
Disturbed
behaviour Low IQ score Brought up in city Cigarette smoking
Poor social
integration
Cannabis (n=5391) 1408 (27) 1582 (31) 297 (6) 2262 (43) 4582 (86) 130 (2.5)
Cannabis only (n=1648) 235 (15) 271 (17) 65 (4) 653 (40) 1331 (81) 34 (2.1)
Any drug (n=11 783) 2325 (20) 2557 (23) 1007 (9) 3358 (31) 8835 (80) 246 (2.3)
No drug (n=36 753) 2827 (8) 1681 (5) 3510 (10) 6759 (19) 19 229 (52) 841 (2.4)
Owing to missing data for each of the confounders, the precentages presented may not tally precisely with the numbers of subjects reported
*Except psychosis or learning disability.
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The crude and adjusted odds ratios with 95% con›
fidence intervals for developing schizophrenia given a
history of ever using cannabis are presented in tables 2,
3, and 4. The crude odds ratio for developing
schizophrenia any time after conscription was 2.2 (1.7
to 2.8) and this association persisted, although
reduced, after adjustment (adjusted odds ratio 1.5, 1.1
to 2.0).
We found a dose dependent relation between
frequency of cannabis use and risk of schizophrenia,
with an adjusted odds ratio for linear trend across the
categories of frequency of cannabis use used in this
study of 1.2 (1.1 to 1.4, P < 0.001). The adjusted odds
ratio for subjects with a history of heaviest use of can›
nabis ( > 50 occasions) was 3.1 (1.7 to 5.5).
The association between cannabis use and schizo›
phrenia was greater in subjects admitted in the first five
years after conscription (adjusted odds ratio 2.1, 1.2 to
3.7) compared with those admitted after five years (1.2,
0.8 to 1.8). Frequency of cannabis use was associated
with schizophrenia in both the early onset group
(adjusted odds ratio for linear trend 1.3, 1.1 to 1.6,
P < 0.001) and the later onset group (1.2, 1.1 to 1.3,
P < 0.02).
Cannabis only
Altogether 1648 subjects (3.3% of cohort, 3.1% to
3.5%) had used only cannabis, and 18 of these (1.1%,
0.6 to 1.7%) developed schizophrenia. Those who used
only cannabis had an increased risk of schizophrenia
compared with those who reported no drug use. The
odds ratio before adjustment (1.9, 1.2 to 3.0) and after›
wards (1.9, 1.1 to 3.1) was similar (table 5). We found a
dose dependent relation for frequency of use, with an
adjusted odds ratio for linear trend of 1.3 (1.0 to 1.5,
P < 0.02).
Stimulant use
We found an association between schizophrenia and
stimulant use in the crude analysis (crude odds ratio
3.8, 2.7 to 5.4), but this became non›significant after
adjustment for confounders (adjusted odds ratio 1.5,
0.9 to 2.4). Adjusting for frequency of cannabis use fur›
ther reduced the association between stimulant use
and risk of schizophrenia (adjusted odds ratio 1.1, 0.6
to 2.1). The association observed between schizophre›
nia and frequency of cannabis use was unchanged after
adjustment for stimulant use.
Other psychoses
A total of 446 subjects were admitted with other
psychoses. Subjects who had ever used cannabis had
an increased risk of developing a psychosis other than
schizophrenia (crude odds ratio 1.4, 1.1 to 1.9), but this
effect was reduced after adjustment (adjusted odds
ratio 1.1, 0.8 to 1.5). A similar pattern was observed for
the association with cannabis frequency, with a linear
trend odds ratio of 1.1 (1.0 to 1.2, P < 0.02) before
adjustment and of 1.0 (0.9 to 1.1, P < 0.85) after
adjustment.
For all the analyses, diagnosis on conscription, IQ
score, and place of upbringing contributed most to
confounding. Adjusting for the other potential
confounders made virtually no difference to the final
adjusted results.
Discussion
Self reported use of cannabis in early adulthood was
associated with an increased risk of developing schizo›
phrenia. Risk increased in a dose dependent manner
with increasing frequency of cannabis use, and this
relation remained when analysis was restricted to sub›
jects who had used only cannabis and no other drugs
before conscription. The largest risk was seen in
subjects reporting use of cannabis on more than 50
occasions. We found no association between cannabis
and other psychotic illnesses, which implies that
cannabis has a rather specific association with an
increased risk of schizophrenia.
Table 2 Crude and adjusted odds ratios with 95% confidence intervals for developing
schizophrenia any time after conscription in subjects who have ever used cannabis
Drug use
No of
subjects
No (%) of subjects
developing
schizophrenia
Odds ratio (95% CI)
Crude Adjusted*
Cannabis ever† 5391 73 (1.4) 2.2 (1.7 to 2.8) 1.5 (1.1 to 2.0)
Frequency of use of cannabis (ever):
None 36 429 215 (0.6) 1.0† 1.0†
Once 608 2 (0.3) 0.6 (0.1 to 2.2) 0.6 (0.1 to 2.3)
2›4 times 1380 8 (0.6) 1.0 (0.5 to 2.0) 0.9 (0.4 to 1.9)
5›10 times 806 9 (1.1) 1.9 (1.0 to 3.7) 1.4 (0.7 to 2.8)
11›50 times 689 13 (1.9) 3.2 (1.8 to 5.7) 2.2 (1.2 to 4.0)
>50 times 731 28 (3.8) 6.7 (4.5 to 10.0) 3.1 (1.7 to 5.5)
Linear trend for frequency of use — — 1.4 (1.3 to 1.5) 1.2 (1.1 to 1.4)
*Adjusted for diagnosis at conscription to IQ score to poor social integration to disturbed behaviour to
cigarette smoking to and place of upbringing.
†No drug use as baseline comparison.
Table 3 Crude and adjusted odds ratios with 95% confidence intervals (95% CI) for
developing schizophrenia in years 0›5 after conscription in subjects who have ever used
cannabis
Drug use
No of
subjects
No (%) of subjects
developing
schizophrenia
Odds ratio (95% CI)
Crude Adjusted*
Cannabis ever† 5320 33 (0.6) 2.2 (1.7 to 2.8) 2.1 (1.2 to 3.7)
Frequency of use of cannabis (ever):
None 36 429 47 (0.1) 1.0† 1.0†
Once 608 0 — —
2›4 times 1380 2 (0.1) 1.1 (0.3 to 4.6) 1.0 (0.2 to 4.4)
5›10 times 806 4 (0.5) 3.9 (1.4 to 10.7) 2.6 (0.8 to 7.9)
11›50 times 689 4 (0.6) 4.5 (1.6 to 12.6) 2.8 (0.9 to 8.8)
>50 times 731 13 (1.8) 14.0 (7.5 to 26.0) 4.7 (1.8 to 12.4)
Linear trend for frequency of use — 1.6 (1.4 to 1.8) 1.3 (1.1 to 1.6)
*Adjusted for diagnosis at conscription, IQ score, poor social integration, disturbed behaviour, cigarette
smoking, and place of upbringing.
†No drug use as baseline comparison.
Table 4 Crude and adjusted odds ratios with 95% confidence intervals (95% CI) for
developing schizophrenia in years 5+ after conscription in subjects having ever used
cannabis
Drug use
No of
subjects
No (%) of subjects
developing
schizophrenia
Odds ratio (95% CI)
Crude Adjusted*
Cannabis ever† 5287 40 (0.8) 1.6 (1.1 to 2.2) 1.2 (0.8 to 1.8)
Frequency of use of cannabis (ever):
None 36 382 168 (0.5) 1.0† 1.0†
Once 608 2 (0.3) 0.7 (0.2 to 2.9) 0.8 (0.2 to 3.2)
2›4 times 1378 6 (0.4) 0.9 (0.4 to 2.1) 0.9 (0.4 to 2.0)
5›10 times 802 5 (0.6) 1.4 (0.6 to 3.3) 1.0 (0.4 to 2.5)
11›50 times 685 9 (1.3) 2.9 (1.5 to 5.6) 2.1 (1.0 to 4.5)
>50 times 718 15 (2.1) 4.6 (2.7 to 7.8) 2.5 (1.2 to 5.1)
Linear trend for frequency of use — — 1.3 (1.2 to 1.4) 1.2 (1.0 to 1.3)
*Adjusted for diagnosis at conscription, IQ score, poor social integration, disturbed behaviour, cigarette
smoking, and place of upbringing.
†No drug use as baseline comparison.
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The association between use of cannabis and
schizophrenia was stronger in subjects who were first
admitted within five years of conscription. One
explanation is that subjects with a prodrome of schizo›
phrenia at conscription may have increased their can›
nabis use, perhaps as a means of self medication.2 But
all subjects were screened at conscription, and we
adjusted for other psychiatric problems recorded at
that time. The relation with cannabis use was also
observed in the later onset group, admitted more than
five years after conscription. It seems more likely that
the reduced association in the group with later onset is
due to misclassification, as the number of people who
discontinued cannabis use accumulated over time.22
Although adjustment for confounders substantially
reduced the odds ratios, adjusting for poor social inte›
gration had only minimal effects. A similar effect was
observed in the original study by Andreasson et al, who
adjusted for the number of friends that the subjects
reported having.4 We used a more comprehensive
measure of social integration as it is likely that on its
own this question was not a strong measure of sociable
personality traits. Personality traits are difficult to
measure accurately, however, and residual confound›
ing remains a possibility. The association between can›
nabis and schizophrenia persisted even after adjusting
for use of alcohol, cigarettes, and other drugs, all of
which are likely to be indicative of risk taking
behaviour. This implies that a shared risk factor (be it
biological, genetic, or through personality traits) for
developing schizophrenia and for using psychoactive
substances does not adequately explain the association
observed.
We are limited in that we have only data regarding
use of cannabis before conscription. But if the pattern
of increased initiation and reduced cessation of drug
use seen in the schizophrenia group persisted after the
time of conscription, this would result in us underesti›
mating the effect size of cannabis. Fewer subjects in this
cohort claimed to have used cannabis and other illicit
drugs compared with similar cohorts that used anony›
mous questionnaires.23 The effect of under›reporting
would again result in an underestimate of the true
effect size. Non›response was similar for subjects devel›
oping schizophrenia and non›cases, although, as a fur›
ther check, we repeated the analyses, having recoded
non›responders as either users or non›users of canna›
bis. This made no difference when recoding was
non›differential between cases and non›cases, but it
increased the odds ratios substantially when recoding
was differential.
It is possible that use of stimulants could explain
the results if stimulants were able to induce a chronic
psychotic illness, identical to schizophrenia. But we did
not find an independent association between use of
stimulants and schizophrenia, although power was
reduced compared with other analyses. Although stud›
ies from the United States have found that initiation of
amphetamine use peaks by age 18›20,22 it is possible
that initiation of stimulants after conscription was
more likely in subjects who had previously used only
cannabis. But the absence of an independent
association with use of stimulants in our data implies
that cannabis is potentially the more important agent.
These findings are in keeping with accumulating
evidence that cannabis has detrimental effects on men›
tal health in some people.3 Molecular studies have
shown that Ä9›tetrahydrocannabinol, the active compo›
nent of cannabis, increases release of dopamine in the
mesolimbic pathway.24 Given the suggested relation
between increased mesolimbic dopamine and positive
symptoms of schizophrenia,25 such observations
provide support for the hypothesis that cannabis may
act as a risk factor for this disorder.
Use of cannabis use has increased substantially
over the past few decades in the United Kingdom, and
50% of the population now report having used canna›
bis at least once.26 If cannabis increases the risk of
schizophrenia by 30%, as implied by these results, then
13% of cases of schizophrenia could be prevented if
cannabis use was eliminated from the population,
assuming that a causal relation between cannabis use
and schizophrenia really exists. The overall weight of
evidence is that occasional use of cannabis has few
harmful effects overall,2 and the drug is less likely to be
used regularly and cause dependence than nicotine.
Nevertheless, these results indicate a potentially
serious risk to the mental health of people who use
cannabis, particularly in the presence of other risk fac›
tors for schizophrenia. Such risks need to be
considered in the current move to liberalise and possi›
Table 5 Adjusted odds ratios with 95% confidence intervals for developing
schizophrenia any time after conscription for subjects taking cannabis only
Drug use
No of
subjects
No (%) of subjects
developing
schizophrenia
Odds ratio (95% CI)
Crude Adjusted*
Cannabis ever† 1635 18 (1.1) 1.9 (1.2 to 3.0) 1.9 (1.1 to 3.1)
Frequency of use of cannabis (ever):
None 36 429 215 (0.6) 1.0† 1.0†
Once 245 0 — —
2›4 times 499 5 (1.0) 1.7 (0.7 to 4.2) 1.9 (0.8 to 4.8)
5›10 times 255 3 (1.2) 2.0 (0.6 to 6.3) 1.7 (0.5 to 5.7)
11›50 times 176 1 (0.6) 1.0 (0.1 to 6.9) 0.8 (0.1 to 6.0)
>50 times 70 4 (5.7) 10.2 (3.7 to 28.3) 6.7 (2.1 to 21.7)
Linear trend for frequency of use — — 1.3 (1.1 to 1.6) 1.3 (1.0 to 1.5)
*Adjusted for diagnosis at conscription, IQ score, poor social integration, disturbed behaviour, cigarette
smoking, and place of upbringing.
†No drug use as baseline comparison.
What is already known about this topic
Use of cannabis has been associated with an
increased risk of developing schizophrenia
Alternative explanations for this association
include confounding by personality or by use of
other drugs such as amphetamines, and use of
cannabis as a form of self medication secondary to
the disorder
What this study adds
Self reported cannabis use is associated with an
increased risk of subsequently developing
schizophrenia, consistent with a causal relation
This association is not explained by sociability
personality traits, or by use of amphetamines or
other drugs
Self medication with cannabis is an unlikely
explanation for the association observed
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bly legalise the use of cannabis in the United Kingdom
and other countries.
We thank Hollie Thomas and Diane McCracken for their help
and advice, and Jonas Sadigh for his help with data
management.
Contributors: SZ contributed to the conception of the study,
data analysis, and drafting of the manuscript. PA contributed to
the conception and design of the study, and drafting of the
manuscript. SA contributed to the conception and design of the
study, and drafting of the manuscript. IL contributed to the
design of the study and drafting of the manuscript. GL contrib›
uted to the conception of the study, data analysis, and drafting of
the manuscript. SZ is the guarantor.
Funding: This research is funded from a clinical training fellow›
ship grant, awarded to SZ by the Medical Research Council, UK
(grant no. G84/5689).
Competing interests: None declared.
1 Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry
1993;163:141›9.
2 Hall W, Solowij N, Lemon J. The health and psychological consequences of
cannabis use. Canberra: Australian Government Publishing Service, 1994.
3 Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001;178:116›22.
4 Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizo›
phrenia. A longitudinal study of Swedish conscripts. Lancet
1987;2:1483›6.
5 Johnson BA, Smith BL, Taylor P. Cannabis and schizophrenia. Lancet
1988;1:592›3.
6 Negrete JC. Cannabis and schizophrenia. Br J Addict 1989;84:349›51.
7 Hall W, Degenhardt L. Cannabis use and psychosis: a review of clinical
and epidemiological evidence. Aust N Z J Psychiatry 2000;34:26›34.
8 Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonus›
ers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr
Scand 1989;79:505›10.
9 Johnstone EC. Schizophrenia. In: Johnstone EC, Freeman CPL, Zealley
AK. Companion to psychiatric studies. 6th ed. London: Churchill
Livingstone, 1998:369›97.
10 Lewis G, David A, Andreasson S, Allebeck P. Schizophrenia and city life.
Lancet 1992;340:137›40.
11 David AS, Malmberg A, Brandt L, Allebeck P, Lewis G. IQ and risk for
schizophrenia: a population›based cohort study. Psychol Med
1997;27:1311›23.
12 Malmberg A, Lewis G, David A, Allebeck P. Premorbid adjustment and
personality in people with schizophrenia. Br J Psychiatry 1998;172:308›
13.
13 Lewis G, David AS, Malmberg A, Allebeck P. Non›psychotic psychiatric
disorder and subsequent risk of schizophrenia. Cohort study. Br J Psychia›
try 2000;177:416›20.
14 Otto U. Function of male youths during military service. A follow›up
study of a youth clientele. Acta Psychiatr Scand 1980;282 (suppl):1›60.
15 World Health Organization. Glossary of mental disorders and guide to their
classification for use in conjunction with International Classification of Diseases.
Eight revision. Geneva: WHO, 1974.
16 Geddes JR, Kendell RE. Schizophrenic subjects with no history of admis›
sion to hospital. Psychol Med 1995;25:859›68.
17 Jablensky A. Epidemiology of schizophrenia: a European perspective.
Schizophr Bull 1986;12:52›73.
18 Kristjansson E, Allebeck P, Wistedt B. Validity of the diagnosis of schizo›
phrenia in a psychiatric inpatient register. Nordisk Psychiatrisk Tidskrift
1987;41:229›34.
19 Greenland S, Rothman KJ. Introduction to categorical statistics. In: Roth›
man KJ, Greenland S. Modern epidemiology. 6th ed. Philadelphia:
Lippincott Raven, 1998:231›52.
20 Zammit S, Allebeck P, Dalman C, Lundberg I, Owen M, Lewis G. Paternal
age as a risk factor for schizophrenia (in press).
21 Zammit S, Allebeck P, Dalman C, Lundberg I, Lewis G. Investigating the
association between cigarette smoking and schizophrenia using a cohort
study (in press).
22 Chen K, Kandel DB. The natural history of drug use from adolescence to
the mid›thirties in a general population sample. Am J Public Health
1995;85:41›7.
23 Andreasson S. Misuse of alcohol and cannabis among young men. Stock›
holm: Karolinska Institute, 1990.
24 Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of
mesolimbic dopamine transmission by a common mu1 opioid receptor
mechanism. Science 1997;276:2048›50.
25 Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a
review and reconceptualization. Am J Psychiatry 1991;148:1474›86.
26 Singleton N, Bumpstead R, O’Brien M, Lee A, Meltzer H. Psychiatric
morbidity among adults living in private households, 2000. London: Sta›
tionery Office, 2001.
(Accepted 12 September 2002)
Papers
page 5 of 5BMJ VOLUME 325 23 NOVEMBER 2002 bmj.com
